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Abstract
Purpose To describe the incidence and drug susceptibil-
ity profiles of uropathogenic extended-spectrum-b-lacta-
mase-producing Escherichia coli (ESBL-EC) during a
10-year period and to identify differences in resistance
patterns between urological and non-urological ESBL-EC
isolates.
Methods Retrospective analysis of 191,564 urine samples
obtained during 2001 to 2010 at the University Hospital
Basel, Switzerland. The computerized database of the
Clinical Microbiology Laboratory and the Division of
Infectious Diseases and Hospital Epidemiology was used to
identify ESBL-EC positive urine samples. ESBL-EC iso-
lates were stratified according their origin into two groups:
Urology and non-Urology isolates.
Results The rate of ESBL-EC positive urine samples
increased significantly during the study period (3 in 2001
compared to 55 in 2010, p \ 0.05). The most active agents
were imipenem, meropenem, and fosfomycin (100 %),
followed by amikacin (99.1 %) and nitrofurantoin (84 %).
The least active substances were ampicillin-clavulanate
(20 %), sulfamethoxazole (28 %), and ciprofloxacin
(29.6 %). ESBL-EC isolates from urological and non-
urological patients showed similar susceptibility profiles.
However, ESBL-EC isolates from urological patients were
significantly less susceptible to ciprofloxacin compared to
non-urological isolates (14.7 vs. 32.7 %, p \ 0.05).
Conclusions The rate of urinary ESBL-EC isolates is
increasing. Their susceptibility to nitrofurantoin, fosfomy-
cin, and carbapenems is excellent, whereas ampicillin-
clavulanate, sulfamethoxazole, and ciprofloxacin demon-
strate only low susceptibility. In particular, the use of
ciprofloxacin should be strictly avoided in urologic patients
with suspicion for an ESBL-EC urinary tract infection as
well as routine antibiotic prophylaxis prior to urological
interventions if not explicit indicated by current interna-
tional guidelines or local resistance patterns.
Keywords Epidemiology  ESBL  Escherichia coli 
Urinary tract infection  Urology
Introduction
The microbial etiology of urinary tract infections (UTI) has
been regarded as well-established and reasonably consis-
tent over the past decades [1]. The majority of cases are
caused by Escherichia coli (EC) that accounts for 70–90 %
of uncomplicated and 50–60 % for recurrent or compli-
cated cases [2, 3]. These infections received little attention
in the past since their treatment was straightforward.
However, the emergence of extended-spectrum-b-
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lactamase-producing Escherichia coli (ESBL-EC) chal-
lenges this statement. Today, up to 50 % of the healthy
population is colonized with ESBL-EC, whereas it was
very uncommon in the past [4, 5]. Treatment options for
infections due to these multidrug-resistant organisms are
limited. Empirical therapy may be inappropriate for ESBL-
EC, resulting in a delay in effective therapy, a longer
hospital stay, and higher costs compared with non-ESBL
infections [6, 7]. A report from the Infectious Diseases
Society of America (IDSA) listed ESBL-EC among the six
drug resistant microbes to which new therapies are urgently
needed [8]. ESBL-EC is most frequently found in urine
samples, challenging commonly used concepts for standard
treatment of UTIs with quinolones or trimethoprim/sulfa-
methoxazole (TMP/SMX). Therefore, microbiologic sur-
veillance data and rates of resistance developing over time
are essential to (1) allow evaluation of appropriate anti-
microbial agents, (2) to improve infection control policies,
and (3) to develop strategies to limit outbreaks of these
infections. However, such long term data are scant in the
literature. The aim of the present study was to describe the
epidemiology of ESBL-EC positive urine samples in the
last decade at our institution, to assess current antibiotic
susceptibility patterns as well as to identify differences in
resistance patterns between urological and non-urological
isolates. In addition recommendations for the treatment of
infections caused by ESBL-EC according to recent guide-
lines [9, 10] were discussed.
Materials and methods
Setting
The University Hospital Basel is a tertiary care center with
780 beds serving approximately 27,000 admissions annu-
ally. The computerized database of the microbiology lab-
oratory and the Division of Infectious Diseases and
Hospital Epidemiology was used to identify urinary sam-
ples with ESBL-EC from January 1, 2001 to December 31,
2010. The study was approved by the local ethics
committee.
Data collection and definitions
A total of 191,564 urine samples from 35,946 patients were
submitted to the microbiology laboratory during the study
period. We identified all Escherichia coli (n = 14 648)
positive samples of which 423 were ESBL-EC positive. As
only the first isolate ESBL-EC positive sample per year
from any one patient was considered, 196 isolates were
included to final analysis (Table 1). Clinical data from
outpatients (n = 61) and inpatients (n = 117) were
retrieved from patient charts. The study population was
divided into two subgroups to identify differences in
resistance patterns between urological (n = 34) and non-
urological isolates (n = 162).
Microbiological analysis
Urine samples were assessed by using CHROMagar ori-
entation medium (Becton–Dickinson BBL Diagnostics,
Sparks, MD, USA). For microbiological detection of
ESBL, standard culture methods were performed in
accordance with the guidelines of the Clinical and Labo-
ratory Standards Institute [11]. Routine susceptibility
testing was performed using microbroth dilution (Micro-
naut-S, Merlin) with the following compounds for ESBL
screening: cefpodoxime, ceftriaxone, ceftazidime, and
aztreonam. If the screening test yielded any positive result,
confirmation testing was performed using Etest strips
(AB Biodisk [now, bioMe´rieux]) containing cefotaxime or
ceftazidime, each tested with and without clavulanic acid.
All ESBL-isolates were confirmed by PCR as described
recently [12].
Table 1 Case characteristics
a ESBL-EC extended-spectrum-
b-lactamase-producing
Escherichia coli, n.a. statistical
analysis not applicable
ESBL-ECa Urology samples Control group p value
Urine samples 196 (100 %) 34 (17.3 %) 162 (82.7 %) n.a.
Patients 178 (100 %) 28 (15.7 %) 150 (84.3 %) n.a.
Median age (range) 63 (18–96) 68 (28–88) 62 (18–96) 0.159
Sex
Male 65 (36.5 %) 20 (71.4 %) 45 (30 %) \0.05
Female 113 (63.5 %) 8 (28.6 %) 105 (70 %)
Collecting technique
Foley catheter 43 (22 %) 10 (29.4 %) 33 (20.4 %) 0.103
Single straight catheterization 17 (8.6 %) 5 (14.7 %) 12 (7.4 %)
Clean catch technique 122 (62.2 %) 15 (44 %) 107 (66 %)
Unknown 14 (7.2 %) 4 (11.8 %) 10 (6.2 %)
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Statistical analysis
Statistical analysis was computed on Statistical Package for
Social Sciences (SPSS, version 20.00; Chicago, IL, USA)
for Windows TM. The comparison of categorical data was
performed using Chi square tests and continuous variables
were compared with Mann–Whitney U tests. A p value of
less than 0.05 was considered to indicate statistical sig-
nificance. The probability density function was computed
with R (R Foundation for Statistical Computing).
Results
General characteristics
Data of 191,564 urine samples from 35,946 patients were
analyzed. E. coli was identified in 7.6 %. (n = 14 449).
Four hundred twenty-three (2.9 %) Escherichia coli iso-
lates were ESBL-EC. Finally, 196 ESBL-EC isolates from
178 patients were included in further analysis. The med-
ian age of the patients was 63 years (range 18-96). The
probability to find an ESBL-EC sample for at a given age
is represented in Fig. 1 for the different subpopulations.
Additional case characteristics are summarized in
Table 1.
Trend analysis
The overall proportion of ESBL-EC positive urine samples
increased significantly during the study period (p \ 0.05).
In this context, only three ESBL-EC positive urine samples
were isolated in 2001 compared to 55 in 2010. The increase
in numbers was significant in both populations (urological
vs. non-urological), respectively (Fig. 2).
Antibiotic susceptibility profiles
The antimicrobial susceptibility profiles are shown in
Table 2. Overall, the most active agents were imipenem,
meropenem, and fosfomycin (100 %), followed by ami-
kacin (99.1 %) and nitrofurantoin (83.8 %). The least
active substances were ampicillin/clavulanate (20 %), sul-
famethoxazole (28 %), ciprofloxacin (29.6 %), doxycy-
cline (31.8 %), and levofloxacin (32 %). Urological ESBL-
EC isolates were significant (p \ 0.05) less susceptible to
ciprofloxacin compared to the control group (14.7 vs.
32.7 %). In addition, a significant (p \ 0.05) difference
regarding the ciprofloxacin resistance over the study period
was observed in the study population. However, this dif-
ference did not reached statistical significance considering
urological samples (p = 0.818) or non-urological samples
(p = 0.074) only.
Origin of ESBL-EC positive urine samples
Of the 196 ESBL-EC positive urine cultures, 64 (32.65 %)
were obtained in the outpatient setting, whereas 132 cul-
tures (67.35 %) were obtained from inpatients. The rate of
ciprofloxacin resistance showed no statistically significant
difference (outpatients: 73.4 %, inpatients: 69 %,
p = 0.581).
Fig. 1 Probability density plot of ESBL-EC positive samples
according to age and subpopulation*. *Each curve (i.e., a probability
density function) represents the relative likelihood for an ESBL-EC
positive samples to take on a given age value
Fig. 2 Overall incidence of ESBL-EC positive urine samples
between 2001 and 2010. Only the first isolate ESBL-EC positive
sample per year from any one patient was considered
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Discussion
Urinary tract infection (UTI) is among the most common
bacterial illnesses occurring in adults. The clinical pre-
sentation varies from asymptomatic bacteriuria (ASB) to
life-threatening urosepsis. Acute uncomplicated UTI occur
in healthy women, while complicated UTI occurs in men or
women with underlying functional or structural genitouri-
nary abnormalities. The majority of cases are caused by a
limited number of bacterial genera. Among both outpa-
tients and inpatients, E. coli is the most important UTI
pathogen. Antimicrobial resistance among E. coli is a
major concern, and in particular, the emergence and spread
of ESBL-EC. ESBLs are plasmid encoded enzymes which
confer resistance against all b-lactam antibiotics except
carbapenems and cephamycins [6]. ESBL frequently bear
resistance genes for additional antibiotic classes, such as
sulfonamides, aminoglycosides, and fluoroquinolones [13].
ESBL-EC strains are frequently isolated from both com-
munity onset uncomplicated UTI and nosocomial UTI. To
guide future recommendations to reduce transmission of
ESBL-EC analysis of such data is of major concern. We
observed a higher rate of ESBL-EC in inpatients compared
to outpatients. However, this observation should be
interpreted with precaution. First, increasing evidence
suggests that the spread of ESBL-EC is more related to the
food chain than to nosocomial transmission. In this context,
very high rates (up to [90 %) of ESBL-EC contaminated
chicken and pork meat were reported [4, 14]. Second, a
recent study could demonstrate a low rate of ESBL-EC
transmission in our institution [12]. Finally, we had only
limited access to microbiological outpatient records of
ESBL-EC positive inpatients prior to hospitalization and
not all of these patients were initially screened for ESBL-
EC. Therefore, it is possible that ESBL-EC positive inpa-
tients might be ESBL-EC positive prior to hospitalization.
Studies exploring risk factors associated with urinary iso-
lation of these pathogens consistently identified compli-
cated UTI as a major risk factor. Rodriguez-Bano et al. [13]
reported independent predictors of ESBL-EC UTI, namely
age [60 years, female sex, diabetes mellitus, recurrent
UTI, healthcare-associated infection, and previous antimi-
crobial use. Due to the emergence of ESBL-EC and high
rates of cross-resistances recommendations to treat
uncomplicated UTI were revised [9, 10, 15, 16]. In our
study ciprofloxacin, levofloxacin, amoxicillin-clavulanate
acid, gentamicin, doxycycline, and sulfamethoxazole did
not show reliable in vitro coverage for ESBL-EC isolates.
In addition, we observed a significant difference between
samples derived from the Department of Urology and the
control group regarding the susceptibility of ESBL-EC to
ciprofloxacin. This may be explained by (1) the commonly
increased age of urological patients with a history of cip-
rofloxacin treatment, (2) the widespread use of ciproflox-
acin in males with only complicated UTIs by definition
resulting in fluorochinolone therapy, and (3) the frequent
use of ciprofloxacin for antibiotic prophylaxis in standard
urological procedures [17, 18]. Therefore, we would not
recommend ciprofloxacin in accordance with current
guidelines in cases where ESBL-EC UTIs are suspected as
well as for standard perioperative prophylaxis [9, 10]. The
only oral agents with reliable in vitro activity against
ESBL-EC detected in our study and reported in the liter-
ature are fosfomycin and nitrofurantoin. Fosfomycin is a
phosphoric acid derivative produced by Streptomyces spp.
which inhibits bacterial cell wall synthesis and decreases
the adherence to the urothelium. It can be orally adminis-
tered as fosfomycin trometamol with a single-dose of 3 g
[19] and is well tolerated with neglectable side effects [20,
21]. The observed high in vitro activity of fosfomycin
highlights this substance as an oral treatment option in UTI
associated with ESBL-EC [22, 23]. However, it has to keep
in mind that the widespread use of fosfomycin might
trigger fosfomycin resistance as reported recently [24, 25].
Nitrofurantoin, a bactericidal drug, is reduced by bacterial
flavoproteins to reactive intermediates which inactivate or
alter bacterial ribosomal proteins and other macromolecules.
Table 2 Overall antimicrobial susceptibility profile of urinary
ESBL-EC isolates
Antimicrobial
class/agent
STa Overall%
susc.
USb%
susc.
CGc%
susc.
p value
Carbapenems
Imipenem 196 100 100 100 n.a.
Meropenem 196 100 100 100 n.a.
Other b-lactams
Ampicillin/
clavulanate
155 20 20.7 23 0.787
Piperacillin/
tazobactam
141 55.4 57.2 54.7 0.828
Fluoroquinolones
Ciprofloxacin 196 29.6 14.7 32.7 \0.05
Levofloxacin 191 32 20.6 34.4 0.117
Aminoglycosides
Gentamicin 84 65.5 64.8 65.7 0.940
Amikacin 112 99.1 94.2 100 n.a.
Others
Sulfamethoxazole 125 28 16 31 0.212
Doxycycline 107 31.8 25 33 0.528
Fosfomycin 83 100 100 100 n.a.
Nitrofurantoin 191 83.8 79.5 84.8 0.447
a ST samples tested
b US urology group
c CG control group), susc. susceptibility, n.a. statistical analysis not
applicable
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A 7-day twice-daily administration of 100 mg nitrofurantoin
macrocrystal is recommended. The ARESC study reported a
high in vitro activity (94.9 %) of fosfomycin to E. coli iso-
lates [3]. Our overall data could confirm this result in ESBL-
EC positive urine samples. However, it has to keep in mind
that both fosfomycin and nitrofurantoin are not currently
licensed for treatment of complicated UTI, and the optimal
dose and duration of therapy for this indication have not been
evaluated in clinical trials. Therefore, fosfomycin, as well as
nitrofurantoin, should be reserved for treatment of uncom-
plicated UTI [16]. None of the ESBL-EC isolates tested
exhibited an in vitro resistance against meropenem and
imipenem. These data are congruent with data from Mody
et al. Tamayo et al. and Alhambra et al. which reported no
resistance of ESBL-EC to another carbapenem, namely er-
tapenem [26–28]. The option of using this b-lactam antibi-
otic once a day makes it a useful parenteral antimicrobial
agent for the treatment of serious UTI in nursing homes and
outpatient clinics. However, an increasing use of carbapen-
ems may also result in antibiotic resistance, and thus, only the
prudent use of these substances may prevent selection
pressure and avoid clinical situations with no further treat-
ment options. In such context, the further spread of the ‘‘real
threat’’ carbapenemase-producing Enterobacteriaceae is of
major concern [29]. Piperacillin/tazobactam showed like-
wise good in vitro against ESBL-EC. However, this is con-
tributed to the so called inoculum effect [30]. Therefore, we
insistently advise against to the uncritical use of piperacillin/
tazobactam in severe disease caused by ESBL producing
organisms. The strengths of our study include the large
sample size used, the long observation period as well as the
broadly distributed and systematically collected isolates.
Limitations were (1) inclusion of E. coli only and (2) the
absence of clinical and outcome data describing the types
and severity of the UTI from which the isolates were derived.
Conclusion
In conclusion, we found an increasing prevalence of ESBL-
EC in the last decade at our institution. ESBL-EC isolates
showed high resistance rates to quinolones and sulfameth-
oxazole. In contrast, the susceptibility of ESBL-EC to car-
bapenems and fosfomycin was excellent. ESBL-EC isolates
from urological patients were significant less susceptible to
ciprofloxacin compared to non-urological isolates. There-
fore, the use of ciprofloxacin should strictly be avoided in
urologic patients with suspicion for an ESBL-EC UTI.
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